CN104039132B9 - 制备主要组织相容性复合物基因修饰小鼠的方法 - Google Patents

制备主要组织相容性复合物基因修饰小鼠的方法 Download PDF

Info

Publication number
CN104039132B9
CN104039132B9 CN201280060540.8A CN201280060540A CN104039132B9 CN 104039132 B9 CN104039132 B9 CN 104039132B9 CN 201280060540 A CN201280060540 A CN 201280060540A CN 104039132 B9 CN104039132 B9 CN 104039132B9
Authority
CN
China
Prior art keywords
human
mhc
polypeptide
microglobulin
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280060540.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104039132B (zh
CN104039132A (zh
Inventor
L·麦克唐纳
A·J·莫菲
C·古雷尔
J·麦克沃克
V·沃罗宁那
F·哈里斯
S·史蒂文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority to CN202110831383.7A priority Critical patent/CN113564188B/zh
Priority to CN201710347715.8A priority patent/CN107254480B/zh
Publication of CN104039132A publication Critical patent/CN104039132A/zh
Publication of CN104039132B publication Critical patent/CN104039132B/zh
Application granted granted Critical
Publication of CN104039132B9 publication Critical patent/CN104039132B9/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201280060540.8A 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法 Active CN104039132B9 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110831383.7A CN113564188B (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法
CN201710347715.8A CN107254480B (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161552587P 2011-10-28 2011-10-28
US201161552582P 2011-10-28 2011-10-28
US61/552,587 2011-10-28
US61/552,582 2011-10-28
US201261700908P 2012-09-14 2012-09-14
US61/700,908 2012-09-14
PCT/US2012/062042 WO2013063346A1 (en) 2011-10-28 2012-10-26 Genetically modified major histocompatibility complex mice

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110831383.7A Division CN113564188B (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法
CN201710347715.8A Division CN107254480B (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法

Publications (3)

Publication Number Publication Date
CN104039132A CN104039132A (zh) 2014-09-10
CN104039132B CN104039132B (zh) 2017-06-16
CN104039132B9 true CN104039132B9 (zh) 2017-09-05

Family

ID=47178940

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201710347715.8A Active CN107254480B (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法
CN201280060540.8A Active CN104039132B9 (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法
CN202110831383.7A Active CN113564188B (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710347715.8A Active CN107254480B (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110831383.7A Active CN113564188B (zh) 2011-10-28 2012-10-26 制备主要组织相容性复合物基因修饰小鼠的方法

Country Status (27)

Country Link
US (3) US9615550B2 (https=)
EP (4) EP3262932B1 (https=)
JP (4) JP6154391B2 (https=)
KR (3) KR102295746B1 (https=)
CN (3) CN107254480B (https=)
AU (3) AU2012324016C1 (https=)
BR (1) BR112014009259A2 (https=)
CA (2) CA3074400C (https=)
CY (2) CY1119657T1 (https=)
DK (2) DK3262932T3 (https=)
ES (3) ES2741649T3 (https=)
HK (1) HK1249712B (https=)
HR (2) HRP20171761T1 (https=)
HU (2) HUE035652T2 (https=)
IL (3) IL232097A (https=)
LT (2) LT3262932T (https=)
MX (3) MX391222B (https=)
MY (2) MY164836A (https=)
NZ (1) NZ734532A (https=)
PL (2) PL3262932T3 (https=)
PT (2) PT3262932T (https=)
RS (2) RS56656B1 (https=)
SG (2) SG11201400933VA (https=)
SI (2) SI3262932T1 (https=)
SM (2) SMT201900478T1 (https=)
WO (1) WO2013063346A1 (https=)
ZA (1) ZA201403085B (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
CN108866101A (zh) 2011-10-28 2018-11-23 瑞泽恩制药公司 人源化il-6和il-6受体
CN111484999B (zh) 2013-02-20 2024-10-25 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
EP3699190B9 (en) 2013-02-22 2023-10-04 Regeneron Pharmaceuticals, Inc. Murine cell expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CA2902543A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
TR201901782T4 (tr) 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
ES2613379T3 (es) 2013-10-15 2017-05-24 Regeneron Pharmaceuticals, Inc. Animales con IL-15 humanizada
CN105578876B (zh) * 2013-10-18 2018-07-13 大鹏药品工业株式会社 制备表达hlai类的非人动物的方法
RU2671101C1 (ru) 2013-11-19 2018-10-29 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
CA2929846C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
CN111690052B (zh) 2014-04-08 2024-06-04 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
EP3636073B1 (en) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
NO2785538T3 (https=) 2014-05-07 2018-08-04
IL287519B2 (en) 2014-06-19 2024-01-01 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
RU2726446C2 (ru) 2014-11-24 2020-07-14 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
HUE064960T2 (hu) 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
CN113412818B (zh) * 2014-12-09 2022-11-04 瑞泽恩制药公司 具有人源化分化簇274基因的非人动物
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
EP4248744A3 (en) 2015-04-06 2023-12-27 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
ES2950399T3 (es) * 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
CN109456942A (zh) * 2017-09-06 2019-03-12 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
RU2020112751A (ru) * 2017-09-29 2021-10-29 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, у которых экспрессируется гуманизированный комплекс c1q
US20190098879A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
EP3772927B1 (en) * 2018-03-24 2025-01-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
IL314733A (en) * 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
AU2020244827A1 (en) * 2019-03-25 2021-09-30 Alexis Bio, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non- human) donor and methods and products relating to same
KR102661779B1 (ko) 2019-04-04 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
IL294356A (en) * 2020-01-10 2022-08-01 Biocytogen Pharmaceuticals Beijing Co Ltd Genetically modified non-human animal with human or chimeric mhc protein complex
CN116848254B (zh) 2020-12-16 2026-03-17 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
WO2022133155A1 (en) * 2020-12-16 2022-06-23 Xenotherapeutics, Inc. Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs
CN118511853A (zh) 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
US20250185635A1 (en) * 2022-03-21 2025-06-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin and mhc loci
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
AU2023347224A1 (en) 2022-09-22 2025-03-20 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
WO2024159071A1 (en) 2023-01-27 2024-08-02 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
TW202520975A (zh) * 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
WO2025064470A1 (en) 2023-09-19 2025-03-27 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059263A2 (en) * 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
JP2007236346A (ja) * 2006-03-10 2007-09-20 Meiji Univ クローン胚の作製方法
EP1878342A1 (en) * 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
US20110008361A1 (en) * 2006-06-09 2011-01-13 Judith Mary Bragger Treatment Method
WO2011004192A1 (en) * 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules
CN101986783A (zh) * 2007-04-23 2011-03-16 先灵公司 抗mdl-1抗体

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501510A (ja) 1989-07-25 1992-03-19 セル　ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
WO1993005817A1 (en) 1991-09-19 1993-04-01 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
CA2246333A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
CA2302779C (en) 1997-09-16 2010-02-02 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
WO1999041365A1 (en) * 1998-02-17 1999-08-19 Ortho-Mcneil Pharmaceutical Inc. H2-o modified transgenic animals
AU1023401A (en) * 1999-10-12 2001-04-23 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002047474A1 (en) 2000-12-13 2002-06-20 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US7663017B2 (en) * 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
US7745690B2 (en) 2004-03-09 2010-06-29 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
EP2153845A1 (en) * 2008-08-13 2010-02-17 Julius-Maximilians-Universität Würzburg Endoglin peptides, vaccines and methods for preparing the same
US9557323B2 (en) 2010-09-24 2017-01-31 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
CN111484999B (zh) 2013-02-20 2024-10-25 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
EP3699190B9 (en) 2013-02-22 2023-10-04 Regeneron Pharmaceuticals, Inc. Murine cell expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
AU2014277092B2 (en) * 2013-06-03 2019-04-04 Theravectys Lentiviral vectors containing an MHC class I, MHC class II, or beta-2 microglobulin upstream promoter sequence
CN105578876B (zh) * 2013-10-18 2018-07-13 大鹏药品工业株式会社 制备表达hlai类的非人动物的方法
EP4248744A3 (en) 2015-04-06 2023-12-27 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059263A2 (en) * 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
JP2007236346A (ja) * 2006-03-10 2007-09-20 Meiji Univ クローン胚の作製方法
US20110008361A1 (en) * 2006-06-09 2011-01-13 Judith Mary Bragger Treatment Method
EP1878342A1 (en) * 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
CN101986783A (zh) * 2007-04-23 2011-03-16 先灵公司 抗mdl-1抗体
WO2011004192A1 (en) * 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules

Also Published As

Publication number Publication date
MX391222B (es) 2025-03-21
SI2770821T1 (en) 2018-01-31
AU2012324016C1 (en) 2018-02-15
JP2014532412A (ja) 2014-12-08
ZA201403085B (en) 2025-07-30
MX355725B (es) 2018-04-27
US9615550B2 (en) 2017-04-11
CN107254480B (zh) 2021-08-10
HK1200272A1 (en) 2015-08-07
JP2019068857A (ja) 2019-05-09
HRP20171761T1 (hr) 2017-12-29
EP3262932B1 (en) 2019-05-15
KR20140089560A (ko) 2014-07-15
PL3262932T3 (pl) 2019-10-31
DK3262932T3 (da) 2019-08-05
ES2741649T3 (es) 2020-02-11
EP4311833A2 (en) 2024-01-31
KR101921126B1 (ko) 2018-11-23
AU2016202688A1 (en) 2016-05-19
AU2017279797B2 (en) 2020-10-22
PT2770821T (pt) 2017-12-18
US10869466B2 (en) 2020-12-22
CY1119657T1 (el) 2018-04-04
EP2770821B1 (en) 2017-09-13
AU2017279797C1 (en) 2021-07-15
CN107254480A (zh) 2017-10-17
IL232097A (en) 2017-06-29
CA3074400A1 (en) 2013-05-02
CN113564188A (zh) 2021-10-29
NZ719373A (en) 2018-06-29
NZ734532A (en) 2022-12-23
SG10201603188SA (en) 2016-05-30
IL232097A0 (en) 2014-05-28
HK1249712B (en) 2020-06-26
MX2014004895A (es) 2014-09-12
US20130111617A1 (en) 2013-05-02
SMT201900478T1 (it) 2019-09-09
CN104039132B (zh) 2017-06-16
PT3262932T (pt) 2019-08-26
AU2012324016A8 (en) 2016-03-03
SMT201700576T1 (it) 2018-01-11
HRP20191420T1 (hr) 2019-11-15
WO2013063346A1 (en) 2013-05-02
LT2770821T (lt) 2017-12-11
CA3074400C (en) 2025-03-25
KR20200013810A (ko) 2020-02-07
EP3563680C0 (en) 2023-08-30
EP2770821A1 (en) 2014-09-03
US20170164590A1 (en) 2017-06-15
DK2770821T3 (da) 2017-11-27
JP6866409B2 (ja) 2021-04-28
AU2016202688B2 (en) 2017-09-28
HUE045879T2 (hu) 2020-01-28
KR20180128494A (ko) 2018-12-03
ES2651517T3 (es) 2018-01-26
JP6154391B2 (ja) 2017-06-28
CY1121869T1 (el) 2020-10-14
IL261239A (en) 2018-10-31
JP2020146041A (ja) 2020-09-17
PL2770821T3 (pl) 2018-02-28
JP2017143840A (ja) 2017-08-24
AU2017279797A1 (en) 2018-01-25
AU2012324016B2 (en) 2016-01-28
IL261239B (en) 2019-11-28
HUE035652T2 (en) 2018-05-28
CA2850387A1 (en) 2013-05-02
US20200375160A1 (en) 2020-12-03
EP3563680B1 (en) 2023-08-30
CN104039132A (zh) 2014-09-10
KR102074145B1 (ko) 2020-02-07
MX376167B (es) 2025-03-07
EP4311833A3 (en) 2024-05-01
MY164836A (en) 2018-01-30
RS59082B1 (sr) 2019-09-30
SG11201400933VA (en) 2014-04-28
JP6574457B2 (ja) 2019-09-11
LT3262932T (lt) 2019-08-26
CN113564188B (zh) 2025-03-04
MX2020010763A (es) 2022-04-01
SI3262932T1 (sl) 2019-09-30
BR112014009259A2 (pt) 2020-10-27
EP3563680A1 (en) 2019-11-06
EP3262932A1 (en) 2018-01-03
AU2012324016A1 (en) 2013-05-16
NZ623456A (en) 2016-05-27
RS56656B1 (sr) 2018-03-30
MY178723A (en) 2020-10-20
IL252022A0 (en) 2017-06-29
KR102295746B1 (ko) 2021-09-01
ES2962287T3 (es) 2024-03-18

Similar Documents

Publication Publication Date Title
CN104039132B9 (zh) 制备主要组织相容性复合物基因修饰小鼠的方法
US20200375159A1 (en) Genetically modified major histocompatibility complex animals
AU2012324016B8 (en) Genetically modified major histocompatibility complex mice
HK1249712A1 (en) Genetically modified major histocompatibility complex mice
EP2967014B1 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
HK40106351A (en) Genetically modified major histocompatibility complex mice
RU2783984C2 (ru) Генетически модифицированные в отношении главного комплекса гистосовместимости мыши
HK40015797A (en) Genetically modified major histocompatibility complex mice
HK40015797B (en) Genetically modified major histocompatibility complex mice
HK1200272B (en) Genetically modified major histocompatibility complex mice
HK1212859B (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
CI03 Correction of invention patent

Correction item: Drawings

Correct: Correct

False: Error

Number: 24-02

Page: full text

Volume: 33

CI03 Correction of invention patent